On the mechanism of the antimycobacterial activity of isoniazid + prothionamide + dapsone (Isoprodian).
Increased antimycobacterial activity of Isoprodian (isoniazid + prothionamide + dapsone) may be due to (i) decreased mutation rate for INH resistance provoked in mycobacteria by DDS (in 2 of 3 strains tested); (ii) leakage of K+, Na+ or Ca++ caused by INH and/or by PTH (in all 3 strains tested), and (iii) indicating damages which may increase the low level penetration of DDS into the cell in sub-MIC concentrations as shown by phage proliferation changes (tested in 1 strain with 1 phage).
D000327:Adsorption; D002118:Calcium / Q000378:metabolism; D002463:Cell Membrane Permeability / Q000187:drug effects; D003622:Dapsone / Q000494:pharmacology*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D007538:Isoniazid / Q000494:pharmacology*; D007539:Isonicotinic Acids / Q000494:pharmacology*; D009154:Mutation / Q000187:drug effects; D009160:Mycobacteriophages / Q000187:drug effects; D009161:Mycobacterium / Q000187:drug effects* / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D011515:Prothionamide / Q000494:pharmacology*; D012964:Sodium / Q000378:metabolism
D004338:Drug Combinations; D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone; D012964:Sodium; D011188:Potassium; D002118:Calcium; D007538:Isoniazid